BMS secures FDA acceptance for Camzyos sNDA
The new application was based on results from the Phase III SCOUT-HCM trial.
Drug Development
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal
FDA grants priority review for Sanofi’s venglustat NDA
Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar
SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative
